“In Silico” Research Finds Therapy Targets for Lung Cancer
The Translational Genomics Research Institute and Scottsdale Healthcare aided by computer models uncovered the courses of lung cancer which may lead to discoveries of new drugs. The study is released in the Journal of Thoracic Oncology. This can be found online, whereas the printed version is expected to see the light in the journal`s November issue.
Leading the team of investigators was doctor Glen Weiss who is the director of the Thoracic Oncology at TGen Clinical Research Services within the Scottsdale Healthcare. He stated that the research presented the benefits of using computer models also known as “in silico” studies.
The TGen Clinical Research Services represents a joint entity of Scottsdale Healthcare and TGen. This partnership enables findings in the molecular and genomic fields and also keeps in touch with interested parties all over the Globe in order to get as fast as possible to the end-user of their studies, meaning the patients located in the Virginia G. Piper Cancer Center at Scottsdale Healthcare. This is achieved in clinical tests with the aid of factors that target specific cancer features.
Those investigators using “in silico” studies hope that this method would lead both to smaller medical care expenses and at the same time prove to be a time-effective mechanism of metamorphosing the virtual findings into new therapies for the people who suffer from cancer.
As doctor Glen Weiss states, some of the cancer courses could be observed from the computer research. This is a very good thing due to the fact that researchers identify new ways to experiment and implement therapies for the ill patients.
The research strived to examine the metabolic courses which could be aimed by the drugs received by the people suffering from small- and large-cell lung cancer. These metabolic paths represent a chain of chemical reactions that take place inside a cell. The small-cell lung cancer sums up 15% of the total number of lung cancers, whereas the others are seen as non-small lung cancer from which 10% is scored by large-cell lung cancers.
The research team studied information made public and focused on the links between various factors that were not noticed in the past investigations.
Doctor Weiss explained that the studied datasets comprised similar courses and provided some examples offered by the computer modeling research. He was aided in his studies by Chris Kingsley, doctor within TGen, and Anoor Paripati, doctor from Scottsdale Clinical Research Institute at Scottsdale Healthcare.
Wnt/ß-catenin represents one pathway identified by their study that can be targeted by vorinostat and dasatinib which are two drugs that are still examined and given only in clinical tests.
The leading author of the study claimed that his team examined public data in order to find some answers. They realized that by looking at various courses of the cancer they would be able to recognize the targets. In order to validate their results, the investigators compared what they observed and the available data.
It seems that nowadays the “in silico” studying is prone to become well known because the National Cancer Institute will release a caBIG which means cancer Biomedical Informatics Grid. The computer modeling research is more cost-effective than developing and analyzing genetic profiles of malign tumors.
This method of analysis is seen as a way to provide new targets for upcoming clinical tests and laboratory investigations. “In silico” research will also aid investigators in coming up with more individualized therapies for ill patients.
As doctor Weiss explains the multitude of data sets will be available in the coming period and with its help the clinicians would be able to create more efficient clinical tests in order to discover the medicines that work the best for the ill person.
